The Latest News and Notes, plus Conversation with Stephen McLeod, MD
Click Here to Manage Email Alerts
Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Stephen McLeod, MD, about his new position and the future of the American Academy of Ophthalmology.
- Welcome to the Eyeluminaries podcast :01
- Review of episode 15, live from Eyecelerator :37
- Preview of episode 17, live at Octane OTS 1:07s
- Théa to acquire seven branded ophthalmic products from Akorn 2:17
- FDA approves Miebo to treat signs, symptoms of dry eye disease 5:11
- OCS-01 eye drops meet primary, secondary endpoints in diabetic macular edema phase 3 trial 8:56
- ‘One of my greatest honors’: Jim Mazzo awarded Ellis Island Medal of Honor 10:38
- Introduction Stephen McLeod, MD 12:14
- What’s been your biggest challenge transitioning from clinical practice to your current position? 14:16
- Where is the AAO going now? 17:50
- Prior authorizations are the bane of operational existence. What is AAOs role in reforming this system? 22:59
- The future of meetings 30:27
- Preview of episode 17 35:44
- Feedback, questions and guest suggestions at eyeluminaries@healio.com 36:47
- Thanks for listening 54:02
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
Stephen McLeod, MD, is the CEO of the American Academy of Ophthalmology.
We’d love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian.
Collapse
Read more about
Click Here to Manage Email Alerts
